[1]杜 丹,陈宝杰,李贤富.营养控制状态评分对肺癌预后的预测价值研究进展[J].陕西医学杂志,2022,51(12):1614-封3.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.035]
　DU Dan,CHEN Baojie,LI Xianfu.Research progress on predictive value of nutritional control status score for prognosis of lung cancer[J].,2022,51(12):1614-封3.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.035]
点击复制

营养控制状态评分对肺癌预后的预测价值研究进展
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
51
期数:
2022年12期
页码:
1614-封3
栏目:
综 述
出版日期:
2022-12-05

文章信息/Info

Title:
Research progress on predictive value of nutritional control status score for prognosis of lung cancer
作者:
杜 丹; 陈宝杰; 李贤富
(川北医学院附属医院肿瘤科,四川 南充 637000)
Author(s):
DU Dan; CHEN Baojie; LI Xianfu
(Department of Oncology,Affiliated Hospital of North Sichuan Medical College,Nanchong 636999,China)
关键词:
肺癌;  营养控制状况评分;  预后;  预测价值;  免疫状态
Keywords:
Lung Cancer;  CONUT score;  Prognosis;  Predictive value;  Immune status
分类号:
R 734.2
DOI:
DOI:10.3969/j.issn.1000-7377.2022.12.035
文献标志码:
A
摘要:
多数肺癌确诊时已是晚期,生存率低,缺乏有效的预后预测指标。免疫及营养状况影响肺癌预后,因此近年来营养控制状态(CONUT)评分对肺癌预后的预测作用逐渐引起重视。CONUT评分基于血清白蛋白、总淋巴细胞计数和总胆固醇三个参数进行综合评分,是反映免疫状态、营养状况以及机体炎症的综合指标。研究显示CONUT评分与肺癌患者总生存期、无病生存期、肿瘤特异性生存期和无进展生存期具有相关性,具有预测肺癌预后的潜在价值。现就CONUT评分对不同病理类型、不同TNM分期、不同治疗模式肺癌预后的预测价值相关研究进展进行介绍。
Abstract:
Most lung cancers are diagnosed at an advanced stage,with a low survival rate and lack of effective prognostic indicators.Immunity and nutritional status affect the prognosis of lung cancer,so in recent years,the nutritional control status(CONUT)score has gradually attracted attention in predicting the prognosis of lung cancer.The CONUT score is a comprehensive score based on three parameters,serum albumin,total lymphocyte count,and total cholesterol.It is a comprehensive index reflecting immune status,nutritional status,and body inflammation.Studies have shown that CONUT score is correlated with overall survival,disease-free survival,tumor-specific survival and progression-free survival of patients with lung cancer,and has potential value in predicting the prognosis of lung cancer.The research progress on the predictive value of CONUT score for the prognosis of different pathological types,different TNM stages,and different treatment modes of lung cancer is introduced.

参考文献/References:

[1] 张 珊,任小平,田应选.老年肺癌患者心理痛苦现状调查及影响因素分析[J].陕西医学杂志,2021,50(2):245-247,250.
[2] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[3] 杨 昕,李和根.肺癌辨证分型研究进展[J].陕西中医,2021,42(9):1313-1316.
[4] 才 昊,韩 亮,李晓飞.LncRNA XIST通过调控miR-186-5p促进非小细胞肺癌的增殖和侵袭实验研究[J].陕西医学杂志,2020,49(7):781-787,803.
[5] Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[6] Niu X,Zhu Z,Bao J.Prognostic significance of pretreatment controlling nutritional status score in urological cancers:A systematic review and meta-analysis[J].Cancer Cell International,2021,21(1):126.
[7] Takagi K,Domagala P,Polak WG,et al.Prognostic signifcance of the controlling nutritional status(CONUT)score in patients undergoing gastrectomy for gastric cancer:A systematic review and meta-analysis[J].BMC Surg,2019,19(1):129.
[8] Takagi K,Domagala P,Polak WG,et al.Prognostic signifcance of the controlling nutritional status(CONUT)score in patients undergoing hepatectomy for hepatocellular carcinoma:A systematic review and meta-analysis[J].BMC Gastroenterol,2019,19(1):211.
[9] Takagi K,Buettner S,Ijzermans JNM.Prognostic signifcance of the controlling nutritional status(CONUT)score in patients with colorectal cancer:A systematic review and meta-analysis[J].Int J Surg,2020,78(1):91-96.
[10] Sahin F,Aslan AF.Relationship between inflammatory and biological markers and lung cancer[J].J Clin Med,2018,7(7):160.
[11] Mandaliya H,Jones M,Oldmeadow C,et al.Prognostic biomarkers in stage Ⅳ non-small cell lung cancer(NSCLC):Neutrophil to lymphocyte ratio(NLR),lymphocyte to monocyte ratio(LMR),platelet to lymphocyte ratio(PLR)and advanced lung cancer inflammation index(ALI)[J].T ransl Lung Cancer Res,2019,8(6):886-894.
[12] Diem S,Schmid S,Krapf M,et al.Neutrophil-to-lymphocyte ratio(NLR)and platelet-to-lymphocyte ratio(PLR)as prognostic markers in patients with non-small cell lung cancer(NSCLC)treated with nivolumab[J].Lung Cancer,2017,111(1):176-181.
[13] Karki R,Man SM,Kanneganti TD.Inflammasomes and cancer[J].Cancer Immunol Res,2017,5(2):94-99.
[14] Wu N,Chen G,Hu H,et al.Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas[J].Nutr Cancer,2015,67(3):481-485.
[15] Li J,Cheng Y,Liu G,et al.The association of pretreatment serum albumin with outcomes in bladder cancer:A meta-analysis[J].Onco T argets Ther,2018,11(1):3449-3459.
[16] Junttila MR,Sauvage FJ.Influence of tumour micro-environment heterogeneity on therapeutic response[J].Nature,2013,501(7467):346-354.
[17] Porter JA,Young KE,Beachy PA.Cholesterol modifcation of hedgehog signaling proteins in animal development[J].Science,1996,274(5285):255-259.
[18] Xiao X,Tang JJ,Peng C,et al.Cholesterol modifcation of smoothened is required for hedgehog signaling[J].Mol Cell,2017,66(1):154-162.
[19] Sheng R,Kim H,Lee H,et al.Cholesterol selectively activates canonical Wnt signalling over non-canonical Wnt signalling[J].Nat Commun,2014,5(1):4393.
[20] Oneyama C,Lino T,Saito K,et al.Transforming potential of Src family kinases is limited by the cholesterol-enriched membrane microdomain[J].Mol Cell Biol,2009,29(24):6462-6472.
[21] Toyokawa1 GT,Kozuma1 Y,Matsubara T,et al.Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma[J].Journal of Thoracic Disease,2017,9(9):2942-2951.
[22] Sawabata N,Miyaoka E,Asamura H,et al.Japanese joint committee for lung cancer registration:Japanese lung cancer registry study of 11,663 surgical cases in 2004:Demographic and prognosis changes over decade[J].J Thorac Oncol,2011,6(7):1229-1235.
[23] Shoji F,Take HN,Akamine T,et al.The preoperative controlling nutritional status score predicts survival after curative surgery in patients with pathological stage Ⅰ non-small cell lung cancer[J].Anticancer Research,2017,37(2):741-747.
[24] Lien YC,Hsieh CC,Wu YC,et al.Preoperative serum albumin level is a prognostic indicator for adenocaarcinoma of the gastric cardia[J].J Gastointest Surg,2004,8(8):1041-1048.
[25] Ray-Coquard I,Cropet C,Van-Glabbeke M,et al.European organization for research and treatment of cancer soft tissue and bone sarcoma group:Lymphopenia as a prognostic factor for overall in advanced carcinomas,sarcomas,and lymphomas[J].Cancer Res,2009,69(13):5383-5391.
[26] Schwegler I,Holzen A,Gutzwiller JP,et al.Nutritional risk is a clinical predictor of postoperative mortality and morbidity in surgery for colorectal cancer[J].Br J Surg,2010,97(1):92-97.
[27] Wang D,Guo D,Shi F,et al.The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer[J].Future Oncol,2019,15(29):3367-3379.
[28] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer sta-tistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[29] Yilmaz A,Tekin SB,Bilici M,et al.The significance of controlling nutritional status(CONUT)score as a novel prognostic parameter in small cell lung cancer[J].Lung Volume,2020,198(4):695-704.
[30] Ohba T,Takamori S,Toyozawa R,et al.Prognostic impact of the controlling nutritional status score in patients with non-small cell lung cancer treated with pembrolizumab[J].Journal of Thoracic Disease,2019,11(9):3757-3768.
[31] Evgeny N,Aglaya G,Evgeny V.Molecular testing and targeted therapy for non-small cell lung cancer:Current status and perspectives[J].Crit Rev Oncol Hematol,2021,157:103194.
[32] Akamine T,Toyokawa G,Matsubara T,et al.Significance of the preoperative CONUT score in predicting postoperative disease-free and overall survival in patients with lung adenocarcinoma with obstructive lung disease[J].Anticancer Res,2017,37(5):2735-4272.
[33] Ettinger DS,Wood DE,Aisner DL,et al.Non-small cell lung cancer,version 5.2017,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2017,15:504-535.
[34] Postmus PE,Kerr KM,Oudkerk M,et al.Early and locally advanced non-small-cell lung cancer(NSCLC):ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2017,28(suppl_4):1-21.
[35] Videtic GMM,Donington J,Giuliani M,et al.Stereotactic body radiation therapy for early-stage non-small cell lung cancer:Executive summary of an ASTRO evidence-based guideline[J].Pract Radiat Oncol,2017,7(5):295-301.
[36] Li L,Wang Y,Yang P,et al.Correlation of the controlling nutritional status score and the prognostic nutritional index with the prognosis of patients treated with radiotherapy for small-cell lung cancer[J].Ann Palliat Med,2021,10(11):11635-11642.
[37] Planchard D,Popat S,Kerr K,et al.Metastatic non-small cell lung cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):192-237.
[38] Takamori S,Ohba T,Shimokawa M.Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer(ICI-PREDICT study)[J].PLoS One,2021,16(10):e0258616.
[39] Gray JE,Villegas A,Daniel D,et al.Three-year overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC-update from PACIFIC[J].J Thorac Oncol,2020,15(2):288-293.
[40] Antonia SJ,Villegas A,Daniel D,et al.Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC[J].N Engl J Med,2018,379(24):2342-2350.
[41] Theelen WSME,Peulen HMU,Lalezari F,et al.Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer:Results of the PEMBRO-RT phase 2 randomized clinical trial[J].JAMA Oncol,2019,5(9):1276-1282.

相似文献/References:

[1]贾丽娟,杜苏丰.重组新城疫病毒疫苗rlRVG对A549荷瘤小鼠瘤体生长的抑制作用[J].陕西医学杂志,2019,(1):6.
　JIA Lijuan,DU Sufeng..The tumor growth influence of recombinant NDV (rlRVG) on lung adenocarcinoma A549transfected in vivo[J].,2019,(12):6.
[2]江茂琼,贾钰铭△,叶文静,等.MDSCs对肺癌小鼠CD8+T细胞及生存期的影响研究[J].陕西医学杂志,2019,(3):293.
　JIANG Maoqiong,JIA Yuming,LI Ting,et al.Effect of MDSCs on CD8 T cells and survival time of lung cancer mice[J].,2019,(12):293.
[3]李君艳,陈国荣.肺癌患者凝血指标与临床特征的关系*[J].陕西医学杂志,2019,(6):718.
　LI Junyan,CHEN Guorong..The relationships between coagulation indicators and clinic characterisitics of patients with lung cancer[J].,2019,(12):718.
[4]王 玲,申 鸿.癌胚抗原、糖类抗原、CA125、血管生成素、细胞角蛋白19片段及甲胎蛋白检测在肺癌诊断中的临床研究*[J].陕西医学杂志,2019,(8):1080.
　WANG Ling,SHEN Hong..The value of tumor markers CEA，CA199，CA125，Ang-2，CYFRA211 and AFP in the diagnosis of lung cancer[J].,2019,(12):1080.
[5]韩 乐,陈文娟△,雷光焰,等.microRNA21、microRNA25在肺癌组织中的表达及意义*[J].陕西医学杂志,2019,(12):1596.
　HAN Le,CHEN Wenjuan,LEI Guangyan,et al.Expression and significance of microRNA21 and microRNA25 in lung cancer tissues[J].,2019,(12):1596.
[6]王 勇,张 勇,白正忠△.单操作孔完全胸腔镜与传统三孔胸腔镜治疗老年肺癌疗效对比研究*[J].陕西医学杂志,2019,(12):1670.
[7]常瑞霞,可春梅.血小板相关参数和凝血指标在肺癌治疗中的变化及意义[J].陕西医学杂志,2021,50(5):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
　CHANG Ruixia,KE Chunmei.Changes and significance of platelet-related parameters and coagulation indexes in treatment of lung cancer[J].,2021,50(12):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
[8]米卫国.负压引流管在单操作孔胸腔镜下肺癌根治术中的临床应用研究[J].陕西医学杂志,2021,50(7):839.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.018]
　MI Weiguo.Application effect of negative pressure drainage tube in patients undergoing radical surgery for lung cancer under single-port thoracoscopy[J].,2021,50(12):839.[doi:DOI:10.3969/j.issn.1000-7377.2021.07.018]
[9]张玉琨,李 波,刘 静,等.迷走神经保护对胸腔镜下肺癌根治术后房颤发生的预防作用[J].陕西医学杂志,2021,50(10):1267.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.023]
[10]米 婷,王雅宁.气管镜下宏基因组学二代测序技术在肺癌鉴别诊断中的临床应用价值[J].陕西医学杂志,2022,51(4):437.[doi:DOI:10.3969/j.issn.1000-7377.2022.04.012]

备注/Memo

备注/Memo:
基金项目:四川省卫生和计划生育委员会科研课题(19PJ037); 医学影像四川省重点实验室开放课题(MIKLSP202107); 川北医学院附属医院科研发展计划项目(2022ZD004)
更新日期/Last Update: 2022-12-05